FDA sets June date for latest review of Merck’s last-ditch antibiotic

FDA sets June date for latest review of Merck’s last-ditch antibiotic

Source: 
Pharmaforum
snippet: 

The FDA has started a six-month priority review of Merck & Co/MSD’s triple antibiotic Recarbrio in a new indication, setting up a possible approval by 4 June.